# Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

> **NCT01392989** · PHASE2 · COMPLETED · sponsor: **Everett Meyer** · enrollment: 44 (actual)

## Conditions studied

- Neural Tube Defects
- Anemia
- Leukemia, Myeloid
- Bone Marrow Transplant Failure
- Myelodysplastic Syndromes (MDS)
- Myeloproliferative Disorders

## Interventions

- **DRUG:** CIK cells
- **DRUG:** Cyclosporine
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Thymoglobulin
- **RADIATION:** Total Lymphoid Irradiation (TLI)

## Key facts

- **NCT ID:** NCT01392989
- **Lead sponsor:** Everett Meyer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2016-06-07
- **Final completion:** 2017-03-19
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2019-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01392989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01392989, "Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01392989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*